- Details
- Description
LUCIGIL (Gilteritinib) is a targeted anticancer medicine containing gilteritinib, a kinase inhibitor that targets FLT3 and AXL signaling pathways. Gilteritinib is designed to inhibit abnormal FLT3 signaling associated with the growth and survival of certain leukemia cells.
Gilteritinib is used for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, when the mutation has been confirmed by an appropriate diagnostic test. Treatment should be selected according to the approved indication and the patient's clinical condition.
LUCIGIL is an oral medicine intended for use under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, monitoring, and management of potential adverse reactions or drug interactions should be determined by the treating physician.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals should consult the applicable official prescribing information before prescribing or dispensing this medicine.
